Eli Lilly, Janssen Pharmaceuticals, MSD, Novartis, Pfizer, Roche, Sanofi, and UCB Pharma., Speakers bureau: Pfizer, Abbvie, Amgen, UCB, BMS, Biogen, MSD, Novartis, Eli Lilly and Company, and Janssen Pharmaceuticals, Anders Odgaard: None declared, Saren Overgaard: None declared, Lene Dreyer Consultant for: MSD, UCB and Janssen Pharmaceuticals, Speakers bureau: MSD, UCB and Janssen Pharmaceuticals, Speakers bureau: UCB, MSD, Eli Lilly and Janssen Pharmaceuticals.


OP0092 ASSOCIATIONS BETWEEN CLINICAL VARIABLES AND PSYCHOLOGICAL SYMPTOMS IN RHEUMATOID ARTHRITIS: A NETWORK SCIENCE PERSPECTIVE

Hsiu Yen Tung1, Sam Norton1, Faith Matcham1, James Galloway1, Matthew Hotopf1. 1King’s College London, London, United Kingdom

Background: Rheumatoid arthritis (RA) is associated with an increased prevalence of common mental disorders, including anxiety and depression (Matcham et al. 2013). Borsboom’s (2017) network theory of mental illness is gaining traction as a model for depression which incorporates biological, social and psychological aspects of depression by looking at interactions between individual symptoms and other variables within a wider network. Currently applications have been restricted to psychiatric samples, however, this model may potentially help gain a clearer understanding of the causal links clinical variables and mental health symptoms in RA.

Objectives: To study the prescriptions of NSAIDs in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) registered in ICEBIO and matched controls, and explore their relationship with disease activity measures. In addition, to explore the impact of initial TNF-α-inhibitor therapy on NSAID prescription rates.

Objectives: To test the feasibility of a network analysis approach to examine associations between clinical variables and mental health symptoms in RA.

Methods: The data used are from patients attending rheumatology clinics at King’s College Hospital who completed patient reported outcomes (PROs) electronically via the Integrating Mental and Physical Healthcare (IMPARTS) system. Over 1,000 patients completed PROs via IMPARTS, with a subsample of 211 extracted for this analysis where psychological screening and inflammatory markers were recorded concurrently (<14 days). The screening tools used were the two-item Patient Health Questionnaire (PHQ2) and the two-item Generalised Anxiety Disorder (GAD2), which assess the core symptoms of depression and anxiety: low pleasure/interest, low mood, high anxiety, uncontrollability of worry. Additional data recorded were joint counts and visual analogue scales for pain, fatigue and global disease activity. Missing data were imputed using multiple imputation. Network analysis was conducted using the ggraph package in R based on the regularised correlations between variables. With a graphical network model of variables created to calculate centrality values.

Results: Figure 1 below illustrates that the symptoms with the most connections were PHQ1 (low pleasure/interest), GAD2 (uncontrollable worry), pain with patient global, tender joints with swollen joints, and ESR with CRP.

The results highlight pain and PHQ2 (low mood) as having both the highest degree (3.9 & 3.8, respectively) and betweenness centrality (22 & 10, respectively). This indicates that these are the variables with both the highest number of connections and providing the shortest pathway between other symptoms and so may act as key variables linking inflammation and mental health. Pain and global disease activity had the highest closeness centrality (0.033 & 0.032, respectively), illustrating that they have the shortest path with all other symptoms and capture the influence of both inflammation and mental health. Tender and swollen joints have weak connections to the mental health variables, suggesting that these extra-articular aspects of pain may be important.

Conclusion: Inflammation in RA does not appear to have a strong influence on mental health, with pain providing the main connection between these areas of the network. Concerning the symptoms of mental health considered, all were strongly connected but low mood provided the main connection between clinical and psychological variables. This indicates mood as potentially a key variable in RA, which is easy to monitor in routine care.

Disclosure of Interests: Hsiu Yen Tung: None declared, Sam Norton: None declared, Faith Matcham: None declared, James Galloway Consultant for: Pfizer Inc, Matthew Hotopf: None declared


OP0093 THE INCIDENCE AND RISK FACTOR OF NEW CAROTID PLAQUES AND THE PROGRESSION RATE OF CAROTID PLAQUES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A 6 YEARS PROSPECTIVE CASE CONTROL STUDY. -TOMORROW STUDY-

Shohei Anno1,2, Kentaro Inoue2, Tadashi Okano2, Kenji Maminoto2, Yukio Sugio2, Masahiro Tada1, Tatsuya Kikko3, Hiroaki Nakamura2, Osaka social medical center, Orthopaedic Surgery, Osaka, Japan; Osaka City University Graduate School of Medicine, Orthopaedic Surgery, Osaka, Japan; Osaka City University Graduate School of Medicine, Center for Senile Degenerative Disorders (CSDD), Osaka, Japan; Osaka City General Hospital, Orthopaedic Surgery, Osaka, Japan; 1Search Institute for Bone and Arthritis Disease (SINBAD), Shihara, Japan

Background: Cardiovascular disease is one of the complications of rheumatoid arthritis (RA). Patients with RA show higher rates of cardiovascular disease mortality and overall mortality compared with individuals without RA. The presence of an abnormality increased intima–media thickness (IMT) in the carotid artery and carotid plaques on carotid ultrasound are useful for assessing the presence of subclinical atherosclerosis. A greater presence of carotid artery IMT and carotid plaques is a predictor of cardiovascular disease events.

Objectives: The objective of this study was to evaluate progression of carotid plaques in 6 years by comparing 2011 and 2017, and to assess the risk factors of progression.

Methods: This study included 208 patients with RA and 204 age- and sex-matched controls (Co) in the Total Management Of Risk factors in Rheumatoid arthritis patients to lower morbidity and mortality (TOMORROW) study. This was a 10-year cohort study that started in 2010. Carotid ultrasound was performed in 2011 and 2017. Ultrasound examination of bilateral carotid arteries was performed using high-resolution B-mode ultrasound (Hitachi Aloka Medical, Tokyo, Japan) with a 6- to 18-MHz linear array transducer. IMT was evaluated as the distance between the luminal–intimal interface and the medial–adventitial interface. IMT was measured using two calipers on the frozen frame of a suitable longitudinal image. The upper limit of normal for IMT was defined as 1.0 mm. Lesions with any focal structure that protruded into the vessel lumen for at least an IMT > 1.1 mm were defined as atherosclerotic plaques. Subsequently, the plaque score was assessed as the sum of the maximal thicknesses of all plaques in bilateral carotid arteries in the scanning area. Plaque scores were categorized as follows: none, no plaques; mild, score of 1.1–5.0; moderate, score of 5.1–10.0; and severe, score of >10.0.

Results: A total of 175 patients with RA (mean age: 58.9 ± 12.7 years, female ratio: 85.7%, mean disease duration: 15.0 ± 11.7 years) and 185 Co (mean age: 58.5 ± 12.5 years, female ratio: 84.3%) were finally analyzed. Carotid plaques were observed more frequently in the RA group than in the Co group in 2011 (n = 82 vs n = 66, p = 0.04). However, the incidence of new plaques was not significantly different between the RA and Co groups (n = 33 vs n = 44, p = 0.94). Age (p = 0.015) and the presence of diabetes (p = 0.009) were higher in patients with RA and new plaques than in those without new plaques. Multivariate logistic regression analysis did not show that RA was a risk factor for the incidence of new plaques (OR: 0.90, 95% CI: 0.47–1.73, p = 0.750). However, the presence of hypertension (OR: 3.11, 95% CI: 1.43–6.74, p = 0.004), the presence of diabetes (OR: 6.13, 95% CI: 1.13–33.4, p = 0.036) were risk factors for the incidence of new plaques. The plaque score became advanced in the RA and Co groups (both p < 0.001) in 6 years.

Conclusion: There are no significant differences in the incidence of new plaques and the progression rate of the plaque score between patients with RA and Co. This finding might due to the recent advances in RA treatment, such as methotrexate or biologic DMARDs. In patients with RA, the presence of hypertension and diabetes represents a risk factor for the incidence of new plaques.


Downloaded from http://ard.bmj.com/ on September 15, 2023 by guest. Protected by copyright.